Physician profile
Charles E Beale
NPI 1407146962
$10,513.80
in general payments reported to CMS, 2019-2025
24 companies · $2,232 in 2025
The $2,232 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,171 · 2020: $168 · 2021: $138 · 2022: $517 · 2023: $578 · 2024: $708 · 2025: $2,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409 · Travel and Lodging: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.75 |
| Travel and Lodging | $1,110.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,321.77 | 2019-2025 | Amplatzer Amulet, Amplatzer |
| Edwards Lifesciences Corporation | $2,747.75 | 2019-2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $1,007.26 | 2019 | |
| Medtronic Vascular, INC. | $675.46 | 2019-2020 | |
| Inari Medical, INC. | $430.60 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $355.30 | 2022-2024 | Corevalve Evolut R |
| Novo Nordisk INC | $282.64 | 2022-2025 | Wegovy, Ozempic |
| Pfizer INC. | $251.10 | 2020-2025 | |
| Penumbra, INC. | $244.54 | 2022 | |
| Novartis Pharmaceuticals Corporation | $217.43 | 2023-2025 | |
| Shockwave Medical, INC | $162.01 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.97 | 2023-2024 | Jardiance |
| Stryker Corporation | $146.20 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Flowtriever |
| E.R. Squibb & Sons, L.L.C. | $88.68 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $81.83 | 2024-2025 | Repatha, Repatha |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $77.43 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $63.65 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $50.00 | 2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.15 | 2024 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $31.21 | 2024-2025 | |
| Philips North America LLC | $27.50 | 2025 | Lm Undivided |
| Actelion Pharmaceuticals US, INC. | $26.30 | 2025 | Opsumit |
| Lexicon Pharmaceuticals, INC. | $22.59 | 2024 | |
| Scpharmaceuticals INC. | $16.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Beale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.